
CDKN2C - Wikipedia
Cyclin-dependent kinase 4 inhibitor C is an enzyme that in humans is encoded by the CDKN2C gene. [5][6][7] The protein encoded by this gene is a member of the INK4 family of cyclin-dependent kinase inhibitors.
CDKN2C Gene - GeneCards | CDN2C Protein | CDN2C Antibody
Mar 30, 2025 · CDKN2C (Cyclin Dependent Kinase Inhibitor 2C) is a Protein Coding gene. Diseases associated with CDKN2C include Hyperparathyroidism and Leukemia, Acute Lymphoblastic. Among its related pathways are Cellular Senescence and Mitotic G1 phase and G1/S transition.
CDKN2C cyclin dependent kinase inhibitor 2C [ (human)]
CDKN2C gene deletion is associated with plasma cell post-transplantation lymphoproliferative disorders. The differences in p18(INK4c)and p57(Kip2)activities in chronic myeloid leukemia and normal stem cells suggest a different cell cycle regulation.
Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical ...
CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion. We tested the clinical impact of 1p deletion and used high resolution techniques to define to role of CDKN2C in primary patient material.
A genome-wide gain-of-function screen identifies CDKN2C as a ... - Nature
Jun 1, 2020 · Validation studies in primary human hepatocytes identified CDKN2C as an important host factor for HBV replication. CDKN2C is overexpressed in highly permissive cells and HBV-infected patients.
CDKN2C cyclin dependent kinase inhibitor 2C [ Homo sapiens …
Dec 10, 2024 · Title: Downregulated miRNA-22-3p promotes the progression and leads to poor prognosis of hepatocellular carcinoma through targeting CDKN2C. miR-21-5p promotes cell proliferation and G1/S transition in melanoma by targeting CDKN2C.
Clinical significance of cyclin-dependent kinase inhibitor 2C ...
Jun 24, 2022 · This study identified upregulated CDKN2C expression and its clinical significance in SCLC and other multiple cancers, suggesting its potential usefulness as a biomarker in treating and differentiating cancers.
CDKN2C - My Cancer Genome
Cyclin-dependent kinase inhibitor 2C (CDKN2C, also known as p18) is a gene that encodes a protein that inhibits the activation of CDK 4 and CDK6. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as bone cancer, endometrial cancer, and intestinal cancer.
CDKN2C cyclin dependent kinase inhibitor 2C - NIH Genetic …
Mar 1, 2024 · Repression of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocytic leukemia. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders.
Entry - *603369 - CYCLIN-DEPENDENT KINASE INHIBITOR 2C; CDKN2C …
Oct 3, 2006 · Members of the INK4 family of CKIs, which includes CDKN2C, specifically bind and inhibit CDK4 (123829) and CDK6 (603368), thereby preventing cyclin D-dependent phosphorylation of RB1 (614041). See INK4D (600947).